Small molecule drug discovery has long been the domain of pharmaceutical companies, and that’s not likely to change anytime soon. But there’s a cadre of universities and nonprofit research institutes that have embraced drug development at its earliest stages, in some cases identifying and optimising compounds that target possible disease-driving proteins discovered in their labs.